Surface Modification of Retroviral Vectors for Gene Therapy by Metzner, Christoph & Dangerfield, John A.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
3 
Surface Modification of  
Retroviral Vectors for Gene Therapy 
Christoph Metzner and John A. Dangerfield 
University of Veterinary Medicine Vienna 
Austria 
1. Introduction 
If biomedicine is considered to be the use of biological or botanical agents in medicine then 
it is certainly the oldest kind of therapy. Since drugs, however, it is no longer the most 
prolifically used, at least in the developed world. Will this change, and if so will it be in the 
near or more distant future? It has been discussed amongst experts in the industry for some 
time that, despite ever-increasing funding and new high-tech methods of discovery and 
screening, amounts of new drugs and drug leads are declining. In part, this has opened the 
way for biologics. The frontrunner is of course antibody technologies, mainly monoclonals, 
the use of which has exploded over the last 5 years to the point where most of the major 
pharma players are involved or are getting involved in what has now become a multi-billion 
dollar industry. Antibodies have reached the point of being a well trusted and accepted 
form of medical product across the industry and communities from bench to bedside.  
Many believe the next similar success story will be for cell therapy, probably some 
differentiated form of stem cells. Although it has been happening for 20 years, it is only in 
the past 5 years that the amount of patients being treated with cells, as a therapy, has 
increased into the thousands per year. The vast majority of these are autologous cell 
treatments, undertaken by hospitals and private clinics on a patient to patient basis using 
the patients’ own cells to treat a wide variety of diseases and conditions. These are not 
officially approved medical products. However, there are several non-pharmaceutical giant 
companies now in clinical trials, notable amongst these are Geron in the USA, Mesoblast in 
Australia and ReNeuron in the UK, although there are some interesting endeavors in 
Southeast Asia too, e.g. Medipost in Korea. All of these are undergoing various stages and 
sizes of clinical trials for diverse indications, some of which are showing already very 
encouraging results. It is predicted that within the next few years one or more of these 
potential products will reach the market as an approved medical product. Having said this, 
other than showing ongoing safety and efficacy in the trials, some hurdles do remain in the 
industry as whole, such as up-scaling for mass production of the cells which is considered 
necessary for generating an off-the-shelf product.  
If this trend continues, it is only reasonable to assume that gene therapy will follow, most 
probably some years after cell therapy has been more widely accepted, but possibly in 
parallel to some extent, as there are also a number of human gene therapy trials already in 
progress. So, how significant will retroviral (RV) and lentiviral (LV) vectors be in this future 
gene therapy industry? One approach to answer this is to look at how popular they have 
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been up to now, both in terms of previous and ongoing trials as well as the interest that the 
research community has in them compared to other forms of gene therapy tools.  
In order to asses this one must firstly consider all forms of gene delivery tools, as this is a 
pre-requisite for gene therapy. In general, gene delivery can be achieved either by viral or 
non-viral means. Mostly, when non-viral gene delivery is discussed, it involves the use of 
plasmid DNA, although there is much interest in other forms of nucleic acids such as 
bacterial artificial chromosomes (BACs) (for recent review on BACs see Tunster et al. 
2011). Nucleic acids can be transduced into the patients’ cells by physical or chemical 
mechanisms. Physical methods include obvious ways like direct injection, or 
aerosolisation/inhalation but also more ingenious techniques like the gene gun or using 
sound waves, such as ultrasound (Passineau et al. 2011) or by electroshock, which can 
intriguingly even work in vivo (De Vry et al. 2010; Kaneda 2010). Such non-viral means 
have classically been considered to be safer because viral vectors may cause insertional 
mutagenesis, revert to wild-type via recombinations during preparation or in vivo with 
other viruses (infections or endogenous viruses). But, at the same time, non-viral means 
are also considered to be far less effective, as once the nucleic acid is inside the cell it is 
only by chance that it will enter the nucleus and be expressed. Both of these views are 
changing somewhat though. From a safety perspective, as techniques for producing and 
detecting virus vectors are advancing and people’s understandings of viral vector safety is 
improving, and, from an efficiency perspective, as chemical and nanomaterial 
technologies improve.  
It boils down to a risk/benefit calculation and viral based methods are still generally 
considered to be far more efficient tools, and as such, outweighing the risks. Mammalian 
cells could be transformed with virus-based methods as early as the 1960’s, yet virus related 
vectorology, with respect to gene delivery, only started to strongly emerge in the early 
1980’s (Figure 1), showing that this is somewhat a matter of definition. In any case, 
adenoviruses (AdV) have always been and still are the most popularly researched and used 
vectors. One would expect that over the years, the number of different types of viruses and 
new viruses being researched as vectors would increase, and this is indeed the case (Fig. 1, 
see “others” from 1 in 1985 to over 400 in 2010). However, one trend that was not as 
expected is that the amount of studies on herpes simplex (HSV) as a vector has not 
increased. In other words, in 1980 the first talk of using viruses in connection with gene 
delivery was concerning HSV (Anderson et al. 1980), by 1985 a few publications related to 
RV, but the most were still HSV related, and surprisingly this number has almost not 
changed up to 2010 where still only approximately 20 publications related to using HSV as a 
vector for gene therapy or delivery. Is it fair to conclude from this that they may simply be 
unsuitable for the job? Further investigation would be required to make such a claim but it 
may be reasonable to suggest that if more successful steps had been made, then increasing 
popularity would be inevitable. Most surprising, however, is that over the last 10 years, 
publications of research and use of viruses as vectors seems to have reached a plateau, and 
in the last four years, have begun to decrease (see Figure 1, All). This may be a sign that that 
some technologies are being absorbed by industrial processes, e.g. patent before publication, 
trade secrets. Such translational activities, although more practical, are less academically 
novel and may reduce the number of research papers.  
Most relevant perhaps for this chapter on surface modifications of enveloped viruses and 
their application, is the changing relationship of interest between RV and LV vectors in the 
research community over the last ten years (Figure 1, compare RV and LV).  
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Fig. 1. The trend of scientific publications in the area of viral vectors for gene delivery over 
the last 25 years. A study was undertaken using the scientific reference collating 
programme, Endnote. The method used was to search and cross-reference various terms. 
For example, both “retrovirus” and “retroviral” were searched together with either “gene 
delivery” or “gene therapy” and “vector” and each were cross-referenced with each other, 
which allowed not only to be sure that the topic in question was relating to gene 
delivery/therapy with viral vectors, and that nothing was missed, but it also gave an idea of 
publications which were using both types of system, i.e. that these were not counted twice. 
The same was done for lentivirus, adenovirus and adeno-associated virus vectors.  
Key: All = total number of all viral vectors for gene delivery and includes the following:  
RV = retroviral vectors; LV = lentiviral vectors; AdV = adenovirus vectors; AAV = adeno-
associated virus vectors; BV = baculoviral vectors; Others = vectors based on the following 
viruses: alphaviruses (e.g. Sindbis, Semliki Forest, Ross River, Venezuelan equine 
encephalitis), vaccinia viruses, poxviruses, infectious bursal disease, herpes simplex, 
Sendai/hemagglutinating virus of Japan, measles, transmissible gastroenteritis virus, 
human and avian influenza, oncolytic vesicular stomatitis, papilloma viruses, lymphocytic 
choriomeningitis, rabies, hepatitis B/C, combinations of viruses (e.g. RV-LV, AdV-RV) as 
well as replicons, amplicons, retroelements and virally related transposons.  
Although the actual numbers are not huge, there is clearly a significant shift in the focus of 
interest from RV vectors to LV vectors. When RV vectors are discussed, this means mainly 
the two forms of murine leukemia virus (MLV), the Friend and Moloney strains, although, 
studies also include vector work with mouse mammary tumour virus (MMTV) and Rous 
sarcoma virus (RSV) (Gunzburg 2003). When LV vectors are discussed, this means mainly 
human immunodeficiency virus type-1 (HIV-1), although again, studies also include vector 
work with simian and feline immunodeficiency viruses (SIV and FIV). There may be many 
reasons for this shift in interest in the scientific community. One is certainly that LV vectors, 
0
200
400
600
800
1000
1200
1400
1600
1800
N
u
m
b
e
r 
o
f 
p
u
b
li
ca
ti
o
n
s 
Year 
All
RV
LV
AdV
AAV
BV
Others
www.intechopen.com
 Viral Gene Therapy 44 
in contrast to RV vectors, offer the ability to transduce non-dividing cells (Sakoda et al. 
2007). This is generally seen as an advantage, however, it may not be desirable in all gene 
delivery cases, as it may be useful to target only dividing cells (e.g. in cancer therapy). 
Another reason is likely to be the sheer amount of interest in HIV as its affliction on humans 
continues to globally expand, i.e. relatively large amounts of finance available and research 
undertaken to understand the virus for human medicine not only leads to drug targets but 
also to ingenious ways of using the virus as a vector for gene delivery or therapy, e.g. self-
inactivating vectors to increase safety (Liehl et al. 2007).  
Other than RV, LV, AdV and AAV, there are many types of viruses being developed as gene 
delivery vectors, all with limited impact, but it seems in more recent years that the numbers of 
these studies are no longer increasing (see Figure 1, Others). One explanation may be that this 
correlates with the amount of new viruses being discovered. Either man has discovered most 
viral entities already or a future technological breakthrough will allow discovery of viral or 
viral related entities of a new dimension. It may also be surprising to some to see how many 
“nasty” viruses are being used to make vectors. For example, HSV BACs were developed 
around 2000 mainly for studying viral genetics, but more recently they are being explored for 
gene therapy (Warden et al. 2011). Other ongoing examples include measles, influenza and 
papilloma viruses, the latter of which cause cancer. When considering this, however, one just 
has to remember what has happened with HIV over the last 15 years. First suggestions of 
using HIV vectors for human medicine were met with serious concern in the general media, 
and even scientists were skeptical, but now they are well accepted and even approved for use 
in human clinical trials (Sheridan 2011, also see below).  
Some publications relate to expression of viral genes within other more common types of 
vector system, e.g. the thymidine kinase gene of the HSV (HSV-TK) expressed using a RV or 
AdV vector, so it is somewhat a matter of definition as to whether they are included as virus 
based gene delivery systems. For this study, such cases were not included. In some cases 
there were also hits for viral components such as the envelope proteins of vesicular 
stomatitis virus (VSV), lymphocytic choriomeningitis virus (LCMV) and amphotropic MLV 
(see also Table 2), but this is relating to pseudotyping, and, although there are a few genuine 
cases of scientists developing true gene delivery vectors from these viruses, the 
pseudotyping cases were not counted in this study. Pseudotyping as a method for viral 
surface modification is discussed later in this chapter. 
Finally, how has all the viral vector research culminated into gene therapy trials in the 
clinic? The majority of trials that have been undertaken and are currently ongoing (around 
14 human trials) are using AdV and AAV (for a recent review see Sheridan 2011). More 
relating to the topic of this chapter, however, are past and ongoing successes for enveloped 
viral vector gene therapies, i.e. RV and LV vectors. Most worthy of mention are the studies, 
human trials and treatments made by Alain Fischer, Marina Cavazzana-Calvo and Salima 
Hacein-Bey-Abina. Children who were suffering from severe combined immunodeficiency 
(SCID-X1) had their T-cells treated ex vivo with a RV vector (Moloney MLV based) to replace 
a defective part of the gene for the interleukin-2 receptor (Cavazzana-Calvo et al. 2000; 
Hacein-Bey-Abina et al. 2008). Although four of the twenty patients treated developed 
leukemia (caused by insertional mutagenesis and activation of a proto-oncogene), they were 
able to be treated for this secondary issue, and seventeen from twenty have had their 
immunodeficiency corrected over the follow-up period of almost 10 years now (Cavazzana-
Calvo et al. 2010). This is a great success in which the benefit clearly outweighed the risk, as 
without alternative treatment (the only one being a bone marrow transplant with only 25% 
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chance of success), the outcome would have been fatal within a few years at best. Other 
ongoing studies in the area of primary immunodeficiency are being undertaken by San 
Raffaele in Italy, also using a Moloney MLV vector (Aiuti et al. 2002), although it is unclear 
if more human trials are planned at present. Two USA companies have ongoing RV vector 
treatments in trials, namely Neurologix for Parkinson’s disease (Kaplitt et al. 2007; Lewitt et 
al. 2011) and Tocagen for a form of brain cancer, glioblastoma multiforme. The Tocagen trial 
is of particular interest as it is the first study in humans using a replication competent RV. 
All RV and LV vectors previously used in trials (even the vast majority used in research) are 
non-replicating or self-inactivating, which means after one round of infection/gene delivery 
that the virus is “dead” and cannot replicate further. It has been classically developed this 
way for safety reasons, unfortunately, as it turns out, the in vivo infection efficiency of such 
vectors may never be good enough for many applications. The MLV based replication 
competent vector developed by Tocagen and its research associates (Anliker et al. 2010) has 
the therapeutic gene, cytosine deaminase (CD), inserted into the viral genome in a stable 
position where the virus cannot easily reject it, even after multiple rounds of infection (Logg 
et al. 2001; Paar et al. 2007). As the RV vector is limited to replicating in dividing cells, and 
only very few cells in the brain are dividing at a speed comparable to the tumour, it is the 
ideal setting. Also, the prodrug used for the treatment, 5-FC, can only pass the blood-brain 
barrier in its non-activated form, i.e. once activated to 5-FU by the CD gene product at the 
cancer location, it cannot pass back into the rest of the body, where there are faster dividing 
cells which could be affected. Once the infected tumour is destroyed, so in turn are the 
replicating viruses in this so called suicide-gene therapy system. This trial is being followed 
by many and with great interest. 
Concerning clinical trials with LV, three companies are worth mentioning. Bluebird Bio 
(formerly Genetix Pharmaceuticals) in the USA, recently completed 2 trials with three 
patients in total who underwent ex vivo treatment of their own hematopoietic stem cells with 
a LV vector delivering corrective genes for either cerebral adrenoleukodystrophy (Cartier et 
al. 2009) or beta-thalassaemia (Cavazzana-Calvo et al. 2010). Although both showed positive 
results, no public announcement on further trials has been announced as yet. Lentigen, also 
in USA, are currently undertaking a pilot study through the University of Pennsylvania for 
several kinds of leukemia and lymphoma, whereby, once again, the patients T-cells will be 
modified ex vivo, but in this case the modification should turn-on the T-cells enabling them 
to attack and trigger the destruction of the cancerous B cells once re-implanted 
(ClinicalTrials.gov Identifier No. NCT00891215). Oxford BioMedica are currently 
undertaking Phase I/II trial for Parkinson’s disease by injecting their LV vector technology 
via stereotactic injection directly into the striatum of patients’ brains. Three genes which are 
necessary for dopamine production should be delivered/expressed and the results are 
predicted to be published soon (EudraCT No. 2007-001109). 
2. Methods to modify surfaces of RV/LV vectors 
2.1 Introduction - proteins of retroviral surfaces 
When retroviral or lentiviral (RV/LV) particles exit infected cells, they are surrounded by a 
lipid membrane, termed the envelope, derived from the infected cells. The envelope 
contains both virus-derived and cellular proteins (VP and CP, respectively), which may 
perform distinct functions for the virus. Since proteins displayed on the envelope are the 
first to make contact with neighboring molecules, they are often involved in virus-cell and 
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virus-medium interactions. In order to complete their life cycle, viruses are depending on 
this communication with their surroundings, specifically the soluble factors (i.e. antibodies 
or proteins of the complement system) contained in the liquid environment and elements 
displayed on the surface of potential host cells (i.e. the receptors found on the cell surface 
required for binding and entry of the virus).  
This is maybe best demonstrated by the VPs found in the lipid membrane of the RV/LV 
particle, termed envelope or Env proteins. The function of these proteins is to initiate cell 
entry (for more details see chapter 3.5.). The RV/LV envelope proteins may be replaced by 
surface glycoproteins of different virus species in a process termed pseudotyping (Bischof 
and Cornetta 2010; Cronin et al. 2005). The resulting viral pseudotypes can be of interest for 
gene therapy applications (see section 2.2. for details). Apart from the virus encoded Env 
proteins, CP are also incorporated into the viral envelopes. Theoretically, this may happen 
as a consequence of three processes: (i) interaction of host proteins with viral proteins (type 
1 incorporation), (ii) incorporation due to directed colocalisation (type 2 incorporation) and 
(iii) random incorporation (type 3 incorporation). The incorporation of the cytoplasmic 
protein cyclophilin A to HIV-1 particles is an example of a type 1 incorporation. The protein 
associates with the viral Gag proteins and is subsequently incorporated with a similar 
efficiency (Hammarstedt and Garoff 2004). A similar situation was shown for the tumor 
susceptibility gene 101 (Tsg-101) product, which presumably has a role in RV/LV particle 
release (Garrus et al. 2001; Pornillos et al. 2003). Additionally, in 1995 the incorporation of 
complement regulatory factors such as CD55 (decay accelerating factor) and CD59 
(protectin) into viral envelopes was described (Breun et al. 1999; Saifuddin et al. 1994; 
Saifuddin et al. 1995; Saifuddin et al. 1997). The levels of these proteins are high enough to 
ensure protection from the human complement system, a part of the innate immune system 
(Breun et al. 1999; Saifuddin et al. 1997). Both the glycosylphosphatidylinositol-anchored 
CD55 and CD59 molecules are enriched in membrane microdomains, often termed lipid 
rafts. Interestingly, it has been demonstrated that a range of viral species including 
retroviruses and lentiviruses may use lipid rafts as sites of viral assembly (Metzner et al. 
2008a). Thus co-localisation of these molecules at the site of viral budding would lead to 
their incorporation into viral envelopes. Thus, this may constitute a type 2 incorporation. 
The co-localisation of molecules at membrane microdomains may also form the framework 
for pseudotyping events (Briggs et al. 2003; Metzner et al. 2008a; Pickl et al. 2001) (see 
section 2.2.). Discriminating between type 2 and type 3 incorporation events may be 
difficult, since directed co-localisation is not easy to demonstrate and the concept of 
membrane microdomains is controversial (Shaw 2006). However, there is reason to believe 
that most incorporation events happen passively (Hammarstedt and Garoff 2004), i.e. 
concentration of proteins is not increased compared to normal membrane composition. To 
maintain a proteome not altogether dissimilar from the cellular membrane may generally be 
beneficial for the virus, since this would contribute to immune-camouflage, i.e. “hiding” the 
virus from the host’s immune system.  
A special case is the exclusion of host proteins from the viral particles. Several cases have 
been described including proteins such as CD45 (Esser et al. 2001), CD4 and the HIV co-
receptors CXCR4 and CCR5 (Lallos et al. 1999). Excluding receptors and co-receptors from 
budding viral particles can be beneficial for the virus, since premature receptor engagement 
and induction of fusion can be avoided. The mechanisms responsible for exclusion of 
proteins from viral envelopes may be that the formation of a network of viral Gag proteins 
inhibits access of proteins with large cytoplasmic domains (such as CD45) or multiple 
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transmembrane passes (such as the HIV co-receptors). Alternatively, involvement of 
excluded proteins in larger complexes may prevent them from being incorporated (such as 
CD4-p56lck). Recently, proteomics approaches have been used to identify host proteins 
found in viral envelopes to get an overview of incorporation (see Table 1) and to date, a long 
list of proteins have been identified in viral particle envelopes (Chertova et al. 2006; Segura 
et al. 2008b) including a range of molecules involved in cellular adhesion. Viruses may profit 
from these molecules, as they can provide additional or indeed, initial anchoring before 
specific interactions between Env and the cognate cell-membrane viral receptors.  
 
Protein Virus Function Comment Reference 
Tsg-101 HIV-1 
MVB sorting;  
HIV budding 
Interaction 
with Gag 
Hammarstedt and Garoff, 
2004; Pornillos et al.; 2002 
CD55 
HIV-1, 
MLV 
Complement 
regulation 
GPI-anchored 
Saifuddin et al., 1995;  
Plewa et al., 2005 
CD59 
HIV-1, 
MLV 
Complement 
regulation 
GPI-anchored 
Saifuddin et al., 1995;  
Plewa et al., 2005 
CD14 HIV-1 
Lipopolysaccharide 
receptor 
GPI-anchored Chertova et al., 2006 
CD29 
(Integrin ß1) 
HIV-1, 
MLV 
Adhesion Random? 
Chertova et al., 2006;  
Segura et al., 2008 
CD44 HIV-1 Adhesion Random? Chertova et al., 2006 
CD54 
(ICAM 1) 
HIV-1 Adhesion Random? Chertova et al., 2006 
CD48 HIV-1 Signaling Random? Chertova et al., 2006 
CD45 HIV-1 Signaling Excluded Esser et al., 2001 
CD4 HIV-1 HIV receptor Excluded Lallos et al., 1999 
CXCR4 HIV-1 HIV co-receptor Excluded Lallos et al., 1999 
CCR5 HIV-1 HIV co-receptor Excluded Lallos et al., 1999 
Table 1. Examples for cellular proteins incorporated to RV/LV envelopes. Tsg tumor 
suppressor gene 101; MVB multivesicular bodies; ICAM intercellular adhesion molecule. 
Surface modification of RV/LV particles can be broadly separated into five categories (see 
Figure 2): (i) pseudotyping, (ii) generation of fusion proteins, (iii) post translational 
modification of proteins with lipophilic residues, most notably glycosylphosphatidylinositol 
(GPI) anchors, (iv) utilization of adaptor molecules, or (v) direct chemical modifications. 
These types of modification will be discussed in sections 2.2. to 2.6., while the purpose of 
such modifications and possible applications will be discussed in section 3. Special attention 
will be given to the “non-classical” methods for modification of viral surfaces discussed in 
section 2.4. to 2.6. 
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Fig. 2. Overview of strategies for modification of RV/LV vector surfaces. 
2.2 Pseudotyping 
The phenomenon that surface (glyco-)proteins of one virus species can be displayed on the 
surface of another retrovirus, or indeed other viral species has been termed “pseudotyping”. 
It was first described more that 55 years ago, after the observation that cells infected with 
two different viruses, can give rise to phenotypically mixed particles (Granoff and Hirst 
1954; Zavada 1982). Interestingly, surface glycoproteins from different families of viruses 
can be exchanged or mixed in such a manner (see Table 2), indicating some degree of 
similarity between these molecules or the mechanisms by which they are incorporated into 
the virions. Because of this compatibility, a limited set of modifications can be introduced to 
retroviral particles by displaying surface molecules of other viral species. Since the primary 
function of viral surface glycoproteins is to mediate binding and entry to host cells, the 
replacement of retroviral Env molecules in most cases changes the infectious range (the 
tropism) of the vector, because different receptors are engaged. This phenomenon can be 
exploited for gene therapy approaches, as it allows for example, the broadening or re-
direction of the virus’ host range (see Table 2). For example, HIV-1 based LV vectors, 
naturally having a very limited, highly specific tropism, infecting only CD4-expressing cells, 
can be redirected from these cells by replacing the Env proteins of HIV-1 with those of the 
vesicular stomatitis virus (VSV), thus generating a vector with a more diverse tropism 
(Bischof and Cornetta 2010). VSV-G, the surface glycoprotein of VSV, is probably the most 
often used molecule for pseudotyping applications. In addition to changing tropism, VSV-G 
also enhances virion stability (Burns et al. 1993) but is toxic to cells if expressed 
constitutively making it challenging to generate stable packaging cell lines. To overcome 
this, tetracycline-inducible promoters are frequently used to generate stable virus-producing 
cell lines (Ory et al. 1996). Additionally VSV-G pseudotypes are highly susceptible to 
inactivation by human serum complement (DePolo et al. 2000) and require additional 
WT surface protein
Pseudotyping
GPI modification
Chimeric proteins
Chemical modification
Adaptor element
Wildtype viral 
surface protein
Heterologous viral 
surface protein
Chimeric viral 
surface protein
Lipid modified non-
viral surface protein
Adaptor i.e. 
Streptavidin
Ligand i.e. biotinyl-
antibodies
Chemically cross-
linked agent
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treatment e.g. by polyethylene glycol (PEG) modification or PEGylation (Croyle et al. 2004). 
Other examples for pseudotyping are described in table 2. It is not in all cases that 
pseudotyping is used to transfer new cell binding properties to the RV/LV vector. Recent 
approaches employ pseudotyping to transfer fusion properties of surface glycoproteins 
from Sindbis (Morizono et al. 2009a; H. Yang et al. 2008a), Influenza (Lin et al. 2001; H. Yang 
et al. 2008a) or measles virus (Anliker et al. 2010; Frecha et al. 2011). In these molecules, 
fusion activity is not strictly dependent on receptor binding. In such cases the original 
binding activity may be abrogated and replaced with a binding function of choice. This 
constitutes a “mixed” modification, since both, pseudotyping and generation of chimeric 
proteins are employed to generate vector particles (see also sections 2.3 and 3.5.).   
 
Viral Surface 
Protein 
Virus Family 
Vector 
Background 
Targeting Preference References 
MLV amphotropic Retroviridae HIV-1, SIV broad, fibroblasts Strang et al., 2004 
GALV Retroviridae HIV-1 
hematopoietic,  
cancer 
Diaz et al., 2000; 
Sandrin  
et al., 2002 
RD114 Retroviridae HIV-1, SIV hematopoietic 
Sandrin et al., 
2002; Zhang et 
al., 2004 
LCMV Arenaviridae 
HIV-1, 
EIAV, SIV 
CNS, glioma,  
pancreas 
Miletic et al., 
2004; Kobinger et 
al., 2004 
Sindbis Togaviridae HIV-1 broad 
Morizono  
et al. 2009 
Ross River Togaviridae HIV-1, FIV Liver (non-hepatocyte) Kang et al. 2002 
VSG-G Rhabdoviridae 
HIV-1, HIV-
2, SIV, FIV, 
EIAV 
CNS, Liver, retina 
Watson et al. 
2002; Park et al. 
2003; Auricchio 
et al. 2001 
Ebola Filoviridae HIV-1, FIV Lung, muscle 
Kobinger et al. 
2004; MacKenzie 
et al. 2002 
Rabies Rhabdoviridae HIV-1, EIAV CNS Stein et al. 2005 
Influenza A Orthomyxoviridae 
HIV-1, 
EIAV, SIV 
Lung McKay et al. 2006 
Measles Paramyxoviridae HIV-1 
broad  
(Edmonston strain) 
Anliker et al. 
2010 
Sendai Paramyxoviridae HIV-1, SIV Liver, Lung 
Kowolik et al. 
2002; Sinn et al. 
2005 
Hepatitis C Flaviviridae HIV-1 Liver Hsu et al. 2003 
Table 2. Examples for the use of pseudotyping events for gene therapy approaches. MLV 
murine leukemia virus; SIV simian immunodeficiency virus; GALV gibbon ape leukemia 
virus; LCMV lymphocytic choriomeningitis virus; EIAV equine infectious anemia virus; 
FIV feline immunodefiency virus; VSV-G vesicular stomatitis virus glycoprotein. 
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The mechanisms behind pseudotyping are believed to be related to the presence of 
membrane subdomains in cellular membranes which function as sites for viral assembly 
and/or budding of a range of different viral species (Briggs et al. 2003; Metzner et al. 2008a; 
Pickl et al. 2001). Since viruses from quite different taxonomical origins are assembled at 
such sites, incorporation of proteins from different virus backgrounds can occur. 
Consequently, pseudotyping can be viewed as a form of type 2 incorporation. Another pre-
requisite for pseudotyping, is that wild-type RV/LV Env proteins are not required for 
functional assembly of virions, inferring that the absence of the native glycoproteins does 
not interfere with particle production. Alternatively, direct or indirect (via a cellular 
intermediate) protein interaction may be responsible for pseudotyping. Recently, an indirect 
interaction model has been proposed using a scanning electron microscopy approach 
(Jorgenson et al. 2009) thus supporting involvement of type 1 incorporation events. To date, 
a large number of combinations have been tried and have been assessed in terms of their 
targeting potential in gene therapy approaches (see Table 2). Recent reviews provide a more 
extensive overview of pseudotyping of RV/LV vectors (Bischof and Cornetta 2010; Cronin 
et al. 2005). 
2.3 Fusion proteins 
Hybrid proteins consisting of amino acid sequence elements derived from more than one 
original polypeptide are termed fusion or chimeric proteins. To avoid confusion with 
proteins such as viral surface glycoproteins exhibiting membrane fusion activity, the latter 
term will be used. The technique of fusing protein parts by manipulation on the DNA level 
has been widely used to study the spatial distribution or kinetics of expression by utilizing 
fluorescent marker proteins such as green fluorescent protein (GFP). Fusing retroviral 
envelope proteins with molecules of interest allows for a more widespread modification of 
viral surfaces, since it is not limited by the availability of naturally occurring viral 
glycoproteins. In the case of chimeric proteins, the residual RV/LV Env molecule part is 
used as a sorting signal, directing the chimeric molecule to sites of budding. The advantage 
of this method is that theoretically no limit is placed on the type of amino acid sequence 
introduced and that incorporation to the viral particle is in most cases efficient (Ryu, 2008). 
The fused parts may be complete ligands (Kasahara et al. 1994), peptides (Gollan and Green 
2002; Morizono et al. 2009a) or single-chain antibodies (Anliker et al. 2010; Somia et al. 1995). 
However, limits have been shown to apply to this technique, as structural or functional 
elements are typically disturbed by their introduction, leading to loss of infectivity, since 
cellular uptake is inhibited at the level of envelope-cell membrane fusion (Galanis et al. 
2001; Ryu et al. 2008; Zhao et al. 1999). When a chimeric Env molecule, containing a CD33 
specific single-chain antibody, was generated to target CD33 positive cells, the collected data 
indicated, that the chimeric protein could not initiate fusion of the virus and cell membranes 
during infection (Zhao et al. 1999). The most widely accepted  explanation for this is that the 
chimeric proteins are unable to undergo a mandatory conformational change which 
activates the fusion activity (see also section 3.5.). Thus, the use of such modifications for 
targeting applications, i.e. the induction of cellular uptake upon engagement of the chimeric 
protein with a cognate receptor, is limited. Inclusion of wild-type RV Env proteins to 
targeted vectors can help to increase infectivity (Tai et al. 2003). This, however, may come at 
a cost for specificity of targeting. Studies conducted on chimeric Moloney murine leukemia 
virus (MoMLV) Env proteins suggest, that addition of as little as two point mutations might 
rescue targeted infection (Zavorotinskaya and Albritton 2001). More recent data suggests 
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that such mutations may need to be determined depending on the characteristics of the 
insert as well as the insertion site (Ryu, 2008).  
However, for purposes other than targeting, such as labeling of viral particles or tagging for 
enrichment purposes, this technique still holds appeal.  A GFP-Env chimeric protein, 
containing the sequence of enhanced GFP fused to the N-terminus of the amphotropic 
4070A Env of MLV has been generated and in this case viral particles retained their natural 
infection range (Spitzer et al. 2003). The construct was used to stain viral receptor-carrying 
cells and may be used for monitoring the dynamics of virus-cell interactions (Spitzer et al., 
2003). An interesting aspect is, that the “virion-targeting functions” of chimeric proteins 
may not necessarily have to be provided by RV/LV Env proteins, but could also be 
provided by the use of cellular proteins present or enriched in viral membranes such as Tsg-
101 (see Table 2).  Alternatively, virion-targeting function may be provided by GPI-
anchoring (see section 2.4.) or indeed, by making use of mixed modifications using fusion 
proteins of non-RV/LV glycoproteins, such as Sindbis virus (Morizono et al. 2009b; Pariente 
et al. 2007) influenza (Lin et al. 2001; L. Yang et al. 2006b) or measles virus (Anliker et al. 
2010; Frecha et al. 2008) with engineered novel binding properties. In these cases the wild-
type binding specificity was destroyed and replaced with molecules conferring specific 
targeting to molecules such as integrin (Morizono et al. 2009a) or the B lymphocyte marker 
CD20 (Anliker et al. 2010). In these cases, membrane fusion activity is inhibited to a lesser 
degree by the change in binding properties. For Sindbis and influenza, virus fusion is 
triggered by a decrease in pH. First in vivo experiments indicated that such vectors can be 
used for targeting applications (Anliker et al. 2010; L. Yang et al. 2006b) (see also section 3.5.) 
2.4 Glycosylphosphatidylinositol (GPI) modification 
GPI anchoring is a type of post-translational modification occurring in eukaryotic cells and 
probably constitutes the most complex and metabolically challenging way of attaching 
proteins to lipid membranes. Proteins targeted for GPI anchoring contain a GPI signaling 
sequence (GSS) at the C-terminal end. The GSS is recognized in the endoplasmatic reticulum 
by the transamidase enzyme complex where it is cleaved at the omega site, the point at 
which the preformed GPI anchor is attached. The biochemical pathway for synthesis of the 
GPI anchors is complex and chemical structures of GPI anchors vary to a great degree 
(Ikezawa 2002) however a common backbone structure is observed: Linkage of the GPI 
anchor to the C-terminal end of the protein is achieved by an amide bond to 
phosphoethanolamine. The following central three mannose residues are linked via a non-
acetylated glucosamine to the phosphoinositol part, which in turn is associated to the lipid 
residues, usually acyl or aryl fatty acid chains or sphingolipids e.g. ceramide (Ikezawa 2002). 
GPI anchored proteins have a variety of different functions. In addition to the mentioned 
complement regulatory activity of CD55 and CD59, GPI-linked proteins serve as hydrolytic 
enzymes like acetylcholinesterase and placental alkaline phosphatase (Ikezawa, 2002) or are 
involved in signal transduction like Thy1 (Haeryfar and Hoskin 2004). They share several 
unique properties: GPI-linked (or “glypiated”) proteins are targeted to the outer surface of 
the cell membrane (Ferguson 1999; Nosjean et al. 1997) and are frequently associated with 
dynamic membrane microdomains also known as lipid rafts (Legler et al. 2005). As 
mentioned previously, they have been suggested as the site of viral assembly for certain 
enveloped viruses e.g. HIV-1 (Briggs et al. 2003; D. H. Nguyen and Hildreth 2000). GPI 
proteins can also be found in serum and other body fluids both with intact or absent GPI 
anchors (Landi et al. 2003). Processes that release GPI-linked proteins into the medium with 
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intact GPI anchors are reversible and it has been shown in a variety of in vitro and in vivo 
systems that GPI-linked proteins can be re-inserted into cell membranes (Dunn et al. 1996; 
Kooyman et al. 1995; Rifkin and Landsberger 1990; Rooney et al. 1993; Rooney et al. 1996; 
Vakeva et al. 1994). Transfer has been demonstrated for CD59 from erythrocytes to 
endothelial cells (Kooyman et al. 1995) as well as for trypanosomal variant surface 
glycoprotein (VSG) to erythrocytes of infected patients (Rifkin and Landsberger 1990). 
Therefore GPI-anchored proteins can be considered to be “hypermobile”. This 
hypermobility allows for the re-integration of purified GPI-anchored proteins to lipid 
membranes of cells (Legler et al. 2005; Medof et al. 1996) and viruses (Metzner et al. 2008b). 
This process has been termed cellular or viral painting, respectively. 
Technically, introducing a GPI anchor to a protein is achieved in the same way fusion 
proteins are made: Following genetic engineering, the recombinant protein is translated and 
the amino acid sequence describing the GSS is included to the nascent polypeptide, thus 
artificially GPI-anchored proteins are produced. A range of recombinant GPI-anchored 
proteins have been produced including glypiated GFP and CD4 (for a review see Metzner et 
al. 2008a). GPI-anchored proteins can be employed for the modification of RV/LV vectors 
by two distinct pathways: (i) after transfection of virus producing cells, facilitated by the co-
localisation of glypiated proteins at the site of viral budding and (ii) by viral painting, re-
introducing purified GPI-anchored proteins to mature viral particles as a result of the GPI-
anchored protein hypermobility.  
Co-transfection of plasmid vectors carrying genes for the production of retroviral vectors with 
constructs expressing the GPI-anchored proteins or super-transfection of pre-existing virus 
producing cell lines, leads to the formation of viral particles displaying GPI-anchored 
molecules on their envelopes. These particles acquire novel properties as a consequence of the 
incorporation of the GPI-anchored protein e.g. super-transfection of the murine retroviral 
producer cell line PALSG/S with the human GPI-anchored protein CD59, yields viral particles 
that are resistant to the activity of complement in human serum (Breun et al. 1999). These 
results suggested for the first time that incorporation of recombinantly expressed GPI-
anchored proteins into the envelopes of viral vectors is possible and that these modifications 
can be useful for gene therapy approaches. In two more recent studies, co-transfection 
approaches successfully produced virus-like particles (VLPs) containing glypiated proteins 
from mammalian (Kueng et al. 2007) or insect cells (Skountzou et al. 2007). In both cases, 
recombinant GPI-anchored different cytokine species were generated i.e. interleukin-2 (IL-2) 
and granuolocyte-macrophage colony stimulating factor (GM-CSF). In the first study, it was 
demonstrated that the GPI-anchored cytokines are functional and elicit cellular responses such 
as differentiation and proliferation with similar efficiency as their soluble counterparts when 
co-cultured with the appropriate target cells (Kueng et al. 2007); and in the second it was 
described that GPI-anchored cytokines engineered onto VLPs based on simian 
immunodeficiency virus (SIV) can enhance immunogenicity of the VLPs. In both cases a 
modulation of the immune responses was achieved by displaying GPI-anchored cytokine 
(Kueng et al. 2007; Skountzou et al. 2007). The major advantage of this approach is that stable 
transfection of RV/LV producer cell lines co- or super-transfected with GPI-anchored proteins 
can provide a reproducible long-term source of modified viral particles. In addition, no post-
exit steps that may reduce infectivity of the vectors are required.   
The second method to modify RV/LV vectors is by using GPI-anchored proteins that have 
been extracted and purified from cells and can be re-inserted after incubation with 
enveloped viruses. This was first described for the GPI-linked model protein CD59his which 
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associates to viral vectors based on MLV and HIV-1 (Metzner et al. 2008b). The association is 
specific and painted virus particles remain infectious after insertion of the GPI-linked 
protein, albeit at reduced efficiencies caused by the duration of the painting process, rather 
than the actual introduction of GPI-anchored molecules into the viral outer shell (Metzner et 
al. 2008b). Estimates of the number of GPI-anchored proteins painted onto retroviral 
particles were in the range of the numbers observed for Env molecules per virion and are 
thus similar to that achieved after incorporation of hybrid proteins produced in co-
transfection experiments (Skountzou et al. 2007). The main advantage of this approach is 
flexibility. Different GPI-anchored proteins can be attached to a range of enveloped viral 
particles without repeated genetic manipulations of the virus-producing cells. This also 
means a considerable gain of time, compared to transfection-based methods. Additionally, 
the amounts of protein deposited at the viral surface are controllable and only a limited 
amount of information about the genetic requirements of the virus is necessary for 
modification. Viral painting may be the method of choice for modification of enveloped 
viral particles in all situations where a degree of flexibility is favourable, e.g. in response to 
genetic heterogeneity in gene therapy approaches or in response to high antigen variability 
for vaccination. Also when genetic modification of virus producing cell lines is difficult, e.g. 
when applying toxic proteins or when genetically or biochemically poorly defined virus 
species are the targets of modification. Viral painting is an example of post-exit surface 
modification, since fully formed viral particles are the target for modification. While 
increasing the flexibility of such approaches, the time invested in modification after exit 
from cells most likely will result in loss of titer (Metzner et al. 2008b) depending on the 
duration of the modification steps. Thus, keeping post-exit incubation times as short as 
possible is vital. 
2.5 Using adaptors structures  
Another strategy to modify viral particles is to introduce adaptor molecule onto the particles 
which in turn can mediate association of other molecules. These adaptors can either be 
soluble, non-covalently attached molecules or membrane bound factors. Soluble adaptors 
have been used to enable targeting strategies in gene therapy. In these cases bispecific 
molecules or assemblies were used, contacting specifically a molecule present on the virus 
and another on the cells about to become infected. These bispecific adaptors or bridge 
complexes can take different forms.  For example, two different antibodies, modified with 
biotin, can be linked via avidin or streptavidin (Roux et al. 1989) thus providing specificity 
for viral surface proteins and the target molecule on the cell. Such a system has been 
proposed as early as 1989, showing directed infection of MHC class I and II expressing cells 
with murine retroviruses (Roux et al. 1989). This system is highly flexible and versatile, since 
a wide range of antibodies which can be biotinylated are available. Pre-treatment of the viral 
vector with the anti-viral antibody would effectively neutralize the viral particle, thus 
increasing the safety of the application. Alternatively, a receptor/ligand chimeric protein, in 
which the binding partner for the viral attachment protein is coupled to a ligand, binding to 
the target molecule on the cell surface may be used. Vectors pseudotyped with Avian 
sarcoma and leukosis virus (ASLV) have been used for implementing such strategies. The 
chimeric bridge protein consisted of the extracellular domains of the cellular receptor for 
ASLV, fused to ligands such as epidermal growth factor (EGF), vascular endothelial growth 
factor (VEGF) or heregulin, thus targeting cells expressing the respective receptors 
(Snitkovsky et al. 2000; Snitkovsky et al. 2001; Snitkovsky and Young 2002). Since these 
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receptors are commonly overexpressed on tumor cells, the approach is already of some 
medical relevance. Instead of the ligands, also single-chain antibodies may be used. An 
approach which has been used for targeting cells expressing a tumor-specific form of the 
EGF receptor (Snitkovsky et al. 2000).  
When using membrane associated adaptors, in most cases, avidin or streptavidin 
engineered to contain a trans-membrane domain are utilised, due to their extraordinarily 
strong affinity to biotin and the comparative ease with which biotin can be attached to a 
wide range of compounds from DNA to antibodies. Avidin and streptavidin molecules are 
available in a wide range of modifications, tailor-made for different applications (Laitinen et 
al. 2007). Again, mixed modifications may be used, by generating fusion proteins of 
avidin/streptavidin with viral surface proteins (M.U. Kaikkonen et al. 2008; M. U. 
Kaikkonen et al. 2009) or even GPI-anchors (Pinaud et al. 2009). The main advantage of this 
system is its flexibility, since factors attached to avidin or streptavidin can be exchanged. 
However, similar to viral painting, post-exit modification steps may be necessary, which 
could potentially reduce infectivity of RV/LV vectors. Such a system has been implemented 
by fusing avidin and streptavidin with the transmembrane domain of VSV-G (M. U. 
Kaikkonen et al. 2009). The binding of biotin to such vectors was demonstrated and they 
could be used for dual imaging and for targeting application (see sections 3.2. and 3.5.). 
Other approaches lead to the biotinylation of the lentiviral vector. This can be achieved by 
direct chemical modification (G. Yang et al. 2006a) (see also section 2.6.) or after addition of a 
biotin-adaptor peptide (BAP), a site for specific enzymatic biotin ligation (G. D. Chen et al. 
2010a; Nesbeth et al. 2006) (see also section 2.6.). The bacterial enzyme, biotin ligase, has to 
be provided as a form of metabolic engineering to allow the modification of the BAP-
containing protein. Both a cellular protein, low-affinity nerve growth factor (Nesbeth et al. 
2006) and a viral protein, Sindbis virus glycoprotein (Morizono et al. 2009b), have been 
modified in such a way to generate novel LV vectors. The latter in fact constitutes 
pseudotyping of an LV vector with a chimeric envelope molecule, containing an adaptor 
element, added by enzyme-mediated covalent chemical modification, thus mixing four 
different strategies to modify viral RV/LV vectors. Alternatively, membrane proteins 
binding antibodies may be used to modify viral surfaces. Insertion of immunoglobulin G-
binding domains (the ZZ domain of staphylococcal protein A) into the Env protein of MLV 
vectors allowed for the binding of specific antibodies directed against the EGF receptor 
HER2. However, infectivity was significantly reduced, as can be expected (Tai et al., 2003). A 
similar approach utilizes a fusion of the same antibody binding domain with Sindbis 
envelope glycoproteins (L. Yang et al. 2006b). The main disadvantage of adaptor systems is 
that an additional, separate element is necessary for the system to work, thus introducing a 
new level of complexity. Additionally, adaptors may dissociate from one or the other 
binding partner, especially if antibody binding domains are used. Competition from serum 
antibodies in vivo may significantly enhance dissociation (Morizono et al. 2009b). Pre-
treatment of viral vectors with the adaptor at least allows administering the virus/adaptor 
complex as a single entity (Boerger et al. 1999). However, adaptor association in most cases 
requires post-exit procedures, which can again contribute to loss of infectivity. 
2.6 Direct chemical modification  
Another option would be the direct chemical linkage of substrates to viral surfaces. While 
successful modification of polymers and polypeptides to adenovirues and adeno-associated 
viruses has been achieved (Croyle et al. 2000; Croyle et al. 2002) it has been difficult to carry 
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out such modifications on RV/LV particles and attempts have been rare. A successful example 
is the attachment of monomethoxy-poly(ethylene)glycol (PEG) to VSV-G pseudotyped LV 
vectors (Croyle et al. 2004). In this case an activated form of PEG is covalently attached to 
lysine residues on proteins displayed on the virus. PEGylation reduces the susceptibility of 
these vectors for the human and murine complement system, while maintaining transduction 
efficiencies (Croyle et al. 2004), thus manipulating the host immune system (see also section 
3.4.). In another, early attempt, MoMLV was modified by chemical addition of carbohydrate 
(galactose) moieties in order to change viral tropism (Neda et al. 1991). Introduction of these 
residues was supposed to specifically infect hepatocytes expressing asialoglycoprotein 
receptors recognizing the carbohydrate moieties on the viral vectors. However, the 
modification resulted in severely reduced infectivity of RV/LV particles. Direct chemical 
biotinylation of retroviral vectors has also been demonstrated, using sulfo-N-
hydroxysuccinimide-biotin MoMLV derived vectors (G. Yang et al. 2006). For this approach 
neutravidin was covalently linked to poly-lysine. The resulting compound was then associated 
to the biotinylated vector. The aim of the study was to allow transduction of human cells with 
ecotropic MLV vectors, which normally cannot infect human cells. In this case, progeny of 
modified viruses would lack the modification, hence infection of neighboring cells, even if 
replication competent vectors were generated, would not be possible. This could contribute to 
safety of gene therapy approaches. Another strategy to biotinylate viral surfaces includes the 
potential for chemical display of biotin using a metabolic engineering approach as  was 
described in section 2.5, i.e. that the introduction of biotin-adaptor peptides to viral surface 
glycoproteins allows for the specific biotinylation of these proteins by a secreted biotin ligase, 
conferring the possibility for avidin, streptavidin or neutravidin linkage. These adaptors can in 
turn be used for attachment of secondary biotinylated compounds (Morizono et al. 2009b). 
Alternatively, desthiobiotin can be metabolically introduced to RV/LV vectors (R. Chen et al. 
2010b). In this case, the binding to avidin and its derivates will be easier to reverse, owing to 
lower affinity. More recently, developments in bioorthogonal chemistry could bring new 
impetus to the field. Bioorthogonal chemistry describes the possibility to allow controlled, 
specific chemical reactions amidst the background of a biological system i.e. in cell culture. 
Specifically, cell surfaces can be modified by oxidation of sialic acids present on glycosylated 
surface proteins by periodate, generating reactive aldehyde groups, which in turn can be 
modified by conjugation of aminooxy-functionalised compounds (Zeng et al. 2009). When this 
technique was applied to cells producing VSV-G pseudotyped MoMLV, resulting viral 
particles carried the modification (S. Wong and Kwon 2011). They used this to introduce 
aminooxy-biotin and could subsequently associate magnetic particles to the virus, facilitating 
purification and concentration of virus preparations (Wong and Kwon 2011; see also section 
3.3.). This approach may also be applied to viral particles post-exit. Direct chemical 
modification of herpesvirus particles with radioactive labels has also been demonstrated and 
was used for biodistribution studies (Schellingerhout and Bogdanov 2002). Biological 
chemistry, by developing bioorthogonal methods, appears to have great potential for novel 
types of modification. 
3. Applications for surface modification of RV 
3.1 General aspects  
The purpose of modifying the surface of RV/LV vectors is to facilitate more efficient delivery 
of the gene of interest to desired sites of expression (see Figure 3). Changes to the viral surface 
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can facilitate this in a number of ways, such as helping to produce more efficient vector stocks 
by enabling purification and concentration of viral vector stocks (thereby helping to increase 
transduction efficiencies) (see section 3.3.), by ensuring optimal interactions with the host 
organism, especially the host’s immune system (see 3.4.), or by limiting viral entry to a subset 
of host cells (see 3.5.). In its simplest form, physical vector surface modification leads to a more 
efficient way of detecting the viral particles, due to the association of labeling molecules, thus 
allowing for a controlled administration and delivery regime (see 3.2.). All of these aspects will 
also help to increase safety of gene therapy approaches, by eliminating potentially toxic or 
immunogenic contaminants and reducing adverse and off-target effects. Suitability of 
modification types for each application will be discussed in the following sections. Another 
important aspect of course is that multifunctional modifications can – and should - be applied 
to allow implementation of different applications such as easy detection by labeling and 
purification/concentration in one modification step. 
 
 
Fig. 3. Overview of applications for surface modifications of RV/LV vectors in gene therapy.  
3.2 Imaging/biodistribution  
Efficiency of gene therapy will be depending on administration regime and the subsequent 
distribution of vectors in the patient. Therefore, these events need to be controlled, already at 
the pre-clinical stages to assess vector performance i.e. in animal experiments. In vivo 
transgene expression analysis, as was used for the detection of specific targeting of LV vectors 
(Pariente et al. 2007) is not ideal, since the information yielded by measurement of 
transduction efficiency or, more generally, transgene expression is different from data 
describing physical particle distribution. Vector particles may be trapped or degraded long 
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before transduction, subsequently not contributing to transgene expression. Thus detection of 
the physical vector particles is required (in addition to and in parallel to transgene expression 
analysis) and may need to be facilitated by labeling of the RV/LV vector particle. Generally, 
labeling approaches should have only minimal to no influence on the performance of the 
RV/LV vector and on the host or target organism (low toxicity and low immunogenicity). 
Another requirement is the stability of label attachment. Loss of label from viral particles 
would not only lead to decrease of signal, but also to an increase of background noise. Finally, 
detection of the label should be easy and easily achievable in vivo. Small, chemically inert 
substances, giving a strong and localized signal, enabling non-invasive detection methods will 
be the ideal tags. For practical reasons, a “one size fits all” approach to labeling may be 
preferred. Flexible and versatile procedures which can be applied to a broad range of RV/LV 
vectors are called for. All mentioned aspects will obviously influence choice of technique for 
labeling and subsequently, location and type of label.  
RV/LV particles can be labeled at the level of the capsid, i.e. using chimeric proteins of 
capsid proteins and fluorescent proteins (Lampe et al. 2007; Lehmann et al. 2005). While loss 
of label will be less of a concern in such circumstances, changing the geometry of the capsid 
might very well have an influence on capsid and/or viral assembly. Modification can also 
be carried out at the level of viral surfaces, where they are much more susceptible to 
dissociation or degradation. So far viral particles are mainly labeled by incorporation of 
chimeric proteins of viral structural proteins and (fluorescent) marker proteins (Lampe et al. 
2007; Lehmann et al. 2005), owing to a high degree of stability of association caused by the 
covalent association. However, fluorescent proteins are comparatively big, increasing the 
chance for steric hindrance and thus influence on vector performance. Detection of 
fluorescence signal may allow for a limited depth of penetration only. Standard 
immunohistochemistry methods use non-protein fluorophore-labelled secondary antibody, 
and while acceptable for in vitro purposes, it cannot provide the stability of a covalent bond 
and therefore may not be suitable for in vivo applications. For the same reason, most 
adaptor-based systems will also not be suitable for labeling, with the possible exception of 
systems using membrane-bound avidin/biotin (M. U. Kaikkonen et al. 2009), due to the 
extraordinarily strong association, which is comparable to covalent interactions. The use of 
GPI-anchored marker proteins provides an alternative, as the modification pathway does 
not interfere with viral structural components, i.e. the envelope surface protein required for 
target cell binding and infection. Infection efficiency is not disturbed by painting (Metzner et 
al. 2008b). The use of viral painting technology can provide the additional advantage of 
flexibility. Incorporation of label is mostly independent of viral producer cell lines and can 
be performed relatively quickly (Metzner et al. 2008b; Metzner et al. 2008a). However, still 
comparatively large polypeptide molecules are attached to the viruses and the degree of 
stability of interaction still needs to be determined. Direct chemical attachment seems to 
have good prospects in this area, since small molecules can be attached to virus particles 
covalently, in a relatively small amount of time (R. Chen et al. 2010b; S. Wong and Kwon 
2011). However, such methods still need to be assessed in terms of their in vivo applications.  
So far fluorescent molecules were considered as primary detection labels. While 
fluorescence detection, together with luminescence has been used for pre clinical in vivo 
detection approaches, it will not be suitable for application in human patients due to low 
penetration depth (Shah et al. 2004). Alternatively, detection based on magnetic resonance 
imaging (MRI) and two radiological methods, positron emission tomography (PET) and 
single photon emission computer tomography (SPECT), may be used (for a review on 
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molecular imaging techniques in gene therapy see Shah et al. 2004; Raty et al. 2007). While 
MRI has been recently utilized for in vivo transgene expression, using ferritin as the reporter 
gene (Hasegawa et al. 2010; M. U. Kaikkonen et al. 2009), SPECT shows promising qualities, 
combining high sensitivity with comparatively low cost equipment and reagents, in 
analyzing physical particle distribution. Such an approach has been utilized to study 
biodistribution of herpes- (Schellingerhout and Bogdanov 2002) and baculovirus (Raty et al. 
2007) in vivo. In these cases the radiolabels were attached to the virus either by direct 
chemical modification (Schellingerhout and Bogdanov 2007) or by adding a biotinylated 
radiolabel to streptavidin modified viral particles (Raty et al. 2007). Dual in vivo imaging of 
rats was demonstrated for LVvectors coding for transferring and displaying streptavidin 
adaptors (M. U. Kaikkonen et al. 2009). In this case, enrichment of iron in cells upon 
transferrin expression was used to enable MRI, while radiolabels were attached to the 
displayed streptavidin molecules to allow for SPECT detection. For this study, deposition of 
adaptor molecules on viral particles was additionally used for targeting applications, 
demonstrating the versatile nature of adaptor systems. However, also approaches using 
fluorescent labeling molecules may additionally have a function in enrichment or 
concentration prior to transduction i.e. viral particles modified with proteins containing 
6xhis-tagged proteins can be enriched by using established immobilized metal ion affinity 
chromatography (IMAC) (Gaberc-Porekar and Menart 2001; Magnusdottir et al. 2009) or 
magnetic purification techniques (Franzreb et al. 2006) (see also section 3.3.).  
3.3 Purification/concentration  
Another important issue in gene therapy is generation of suitable vector preparations in 
terms of viral titer, purity, speed and costs. Cheap methods which allow for quick 
concentration and purification of RV/LV vectors after harvesting from producing cell lines 
are of great importance. Contaminants from producing cell cultures may inhibit 
transduction of target cells (Rodrigues et al. 2007). Additionally, with clinical use of vectors 
as a mid- to long-term aim, vector preparations need to be compliant with regulators’ 
standards. In nearly all cases, purification and concentration of viruses starts with a micro-
filtration step, using 0.45 μm filters to remove cells and cellular debris from culture 
supernatants. When large amounts of dead cells are present in the supernatant, 
centrifugation may be preferred for removal of micro-level contaminants. Subsequently, 
RV/LV particles are still concentrated and purified in most cases by ultra-centrifugation, 
often utilizing sucrose gradients to prevent mechanical damage to viruses. These methods 
are time-consuming and require the use of expensive equipment, i.e. high velocity 
centrifuges. Additionally, not all RV/LV vectors tolerate ultra-centrifugation well. Sucrose 
may need to be removed from preparations afterwards, adding another preparatory step. 
Additionally, high sucrose content can harm virus by change in osmotic pressure. Taken 
together these aspects lead to often quite significant reductions of infectivity (Rodrigues et 
al. 2007). Using VSV-G pseudotypes as well as ultra-centrifugation-resistant virus strains 
can improve yield after ultra-centrifugation (Burns et al. 1993). While acceptable for 
laboratory scale preparation, ultra-centrifugation is unsatisfactory for larger scale 
preparations. Alternatively viruses may be concentrated and purified by ultra-filtration or 
dialysis protocols, separating virus and contaminants according to size using semi-
permeable membranes. Conventional column based methods lead to problems regarding 
large-scale preparations, but use of tangential flow devices can circumvent this aspect 
(Geraerts et al. 2005; Kuiper et al. 2002).  
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What these methods have in common is that they do not rely on any modification of the 
virus. This is partially also true for purification strategies involving chromatography 
applications e.g. size exclusion or ion exchange approaches, both of which have been used 
for purification and concentration purposes (Rodrigues et al. 2007). Affinity 
chromatography is a very powerful tool for removal of contaminants. Using naturally 
occurring affinity tags for purification and concentration such as heparin can work well 
(Segura et al. 2008a; Segura et al. 2010). In such an application the tag should interfere 
minimally with the virus activity, be easily accessible for the purification matrix and, in 
most cases, a transient interaction would be preferred, allowing for removal of virus under 
mild conditions. An additional advantage would be, if the same strategy would be 
applicable for a broad spectrum of vectors. After all, the key property of a purification label 
would be its affinity and specificity for the purification matrices used. Approaches utilising 
either biotin-streptavidin interactions or IMAC have been reported (Williams et al. 2005a; 
Williams et al. 2005b; Ye et al. 2004). In the latter strategy, the affinity of complexed nickel or 
cobalt ions to stretches of histidine aminoacids is exploited. Viruses may be modified for 
application of the streptavidin/biotin system in numerous ways, as described in sections 2.5 
and 2.6. Direct chemical modification was chosen to biotinylate retroviral vectors prior to 
purification using a streptavidin coated stationary phase (Chan et al. 2005; Williams et al. 
2005a; Williams et al. 2005b). As a result of the strong interaction of biotin and 
avidin/streptavidin, removal of viral particles from the purification matrix can require 
harsh conditions, which will reduce yield and infectivity of viral preparations. While IMAC 
was used successfully on viral vectors containing histidine tags in the Env protein (Ye et al., 
2004), immediate dialysis of resulting samples is necessary to remove the chemicals 
necessary for desorption (imidazole, EDTA). These compounds would also need to be 
removed prior to any clinical application, as well as metal ions potentially leaking from the 
purification matrix, since both may lead to adverse side effects in patients (Rodrigues et al. 
2007). In addition to chromatography based methods, attachment of magnetic particles to 
the viral vectors may enable purification and concentration. Recently, attempts have been 
made to attach micro- or nanoparticles with magnetic properties to modified viral surfaces 
(R. Chen et al. 2010b; M. U. Kaikkonen et al. 2009; Nesbeth et al. 2006; S. Wong and Kwon 
2011). Again, avidin-biotin interactions were exploited to attach the magnetic particles. Such 
approaches are interesting due to their potential for up-scaling. Ideally, magnetic 
nanoparticles could be designed in such a way, that they may not have to be removed from 
viruses, but may serve additional function as contrast agents in detection via MRI. 
Generally, adaptor approaches can be considered most useful for labeling purposes, if only 
due to their versatility. Indeed, when an adaptor is present on a viral vector, it may as well 
be used for purification purposes in addition to the primary aim of modification, i.e. 
transduction targeting. Alternatively, quick post-exit approaches, such as viral painting with 
GPI-anchored proteins may be used, giving a great degree of flexibility, as they can be 
applied to a wide range of viral preparations, and again more than one objective may be 
achieved by a single modification i.e. by the use of a histidine-tagged, GPI-anchored 
immunomodulatory protein.  
3.4 Modulation of host functions 
Depending on the administration protocol planned, RV/LV vectors used in gene therapy may 
have to find their way to the target cells. During this journey, they will share contacts with 
both soluble and cell bound components of the host. Elements performing functions in the 
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host’s immune system will be of special interest, since in most patients, gene therapy vectors, 
including RV/LV vectors, will encounter an intact immune system. Navigating the immune 
system will be vital to any successful gene therapy approach. Interaction of virus particles with 
host molecules including immunological reactions are often mediated by molecules located in 
the envelope, thus modifying the envelope with immunologically competent molecules, e.g. 
cytokines or growth factors, allows for the manipulation of surrounding immune responses. 
This specifically includes protection of viral vectors from unwanted immune reactions such as 
complement activity. Immunoprotection can help to ensure efficient delivery to target cells by 
eliminating premature inactivation of vectors in gene therapy approaches. One example is the 
pegylation of VSV-G pseudotyped vectors (Croyle et al. 2004), as discussed in section 2.6. 
Other approaches to protect from complement activity include the introduction of 
complement regulatory factors such as CD55 or CD59 (Breun et al. 1999), if they are not 
already part of the envelope protein contents. In this case the presence of naturally occurring 
GPI-anchored proteins was exploited.  
Protection from the complement or neutralizing antibodies is only one aspect of immune-
modulation. Stimulation of immune responses may be a desired effect to augment 
therapeutic effect i.e. in cancer gene therapy or vaccine strategies. For example, presentation 
of antigen on the surface of virus-like particles (VLPs) is possible via the use of GPI-
anchored molecules. GPI-anchored cytokines engineered onto simian immunodeficiency 
virus (SIV) can enhance immunogenicity of the VLPs (Skountzou et al. 2007). VLPs can be 
used to modulate the immune system in several ways (Kueng et al. 2011). These aspects may 
be of more importance in the development of vaccines or specific adjuvants enhancing 
vaccine efficacy, but variations may also prove useful for gene therapy approaches. For 
example, early acting cytokines such as interleukin 6, stem cell factor or thrombopoietin, 
have been shown to enhance gene transfer using RV/LV vectors to haematopoietic stem 
cells (Santoni de Sio et al. 2006; Zielske and Gerson 2003). Attachment of such factors to viral 
surfaces as discussed above can help to achieve stronger local effects. This may be 
considered also in the context of “targeting by activation”, whereby efficient transduction is 
dependent on activation of the target cell by the ligand/receptor interaction (Verhoyen and 
Cosset 2004; see also section 3.5.).  
A further aspect of modulation of host cell function is inducing differentiation e.g. for tissue 
engineering purposes. Proof of principle was shown through differentiation of monocytes to 
dendritic cells (Kueng et al. 2007). Again, the GPI-anchored cytokines used were functional 
and elicited cellular responses such as differentiation and proliferation with similar 
efficiency as their soluble counterparts when co-cultured with the appropriate target cells. 
The major advantage of this approach is that stable transfection of RV/LV producer cell 
lines co- or super-transfected with GPI-anchored proteins can provide a long-term source of 
modified viral particles reproducibly. In addition, no post-exit steps that may reduce 
infectivity of viral vectors are required. Alternatively, viral painting may be used in cases 
where flexibility is required. Immunomodulation appears to be an area of great possibilities, 
allowing potentially for the “fine tuning” of gene therapy approaches, by enhancing 
distribution or transgene expression and  providing additional beneficial side effects such as 
increased tumor cell killing. 
3.5 Infection targeting 
A key element of successful and efficient gene therapy is the ability to target only a certain 
subset of cells for treatment after systemic administration. This constitutes both, a measure 
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to ensure safety, since (ideally) no non-target cells should become genetically modified, and 
enhance efficacy, since (again, ideally) all vector particles present should recognize and 
infect target cells. Targeted infection is an especially important feature when using 
replication-competent vectors. Such vectors can replicate in infected cells and produce 
progeny virus which in turn can infect new target cells. Whilst highly efficient, i.e. in the 
case of tumor gene therapy, safety of course is an important issue, as a form of viremia is 
part of the delivery strategy, which needs to be tightly controlled. Additionally, infection 
targeting is equally important for all in vivo  gene therapy approaches (as opposed to ex vivo 
approaches, were infection can be limited by other means), especially upon systemic 
administration. Here, viral vectors are introduced to the patient and non-specific infection is 
a definitive risk, especially considering integration of viral DNA into the host genome and 
the associated potential for insertional mutagenesis.  
In the case of RV/LV vectors, the viral glycoproteins located in the envelope function as 
recognition and entry devices to allow access to the target cells. The so called Env proteins 
consist of two subunits, the surface (SU) and transmembrane (TM), both with distinct 
functions. The Env protein complex is a hexamer consisting of 3 copies of each of the TM 
and SU subunits. SU mediates the first contact to the host cells by engaging the viral 
receptor and, eventually co-receptors. The binding specificity of the SU subunit therefore 
determines the host cell range of the virus. Upon this first contact, TM activates fusogenic 
properties, which allow viral and cellular membranes to fuse, resulting in viral entry. The 
interaction of SU and TM is highly sensitive to changes in SU and already small changes can 
disturb the activation of the TM activity (Zhao et al. 1999). Subsequently, modifications 
introduced to the Env proteins are tolerated badly, quite often leading to severe reduction in 
infectivity. Nevertheless, modification of these properties is crucial to achieve infection or 
transduction targeting – one of the most important goals of viral gene therapy. The choice of 
method being used for targeting applications may also be influenced by the specific target 
molecule, cell or tissue and the target’s distribution in the organism, since access to the 
targets will add additional obstacles to delivery/targeting, for example regarding the 
stability of the interaction between viral vector, targeting molecule and target. In targeting 
approaches, specificity is the most important parameter.  
A range of different strategies have been tested to change the infection tropism including the 
use of glycoproteins from heterologous viral species (pseudotyping) or chimeric envelope 
glycoproteins (Env fusion proteins) as well as bridging molecules (adaptors) (Waehler et al. 
2007). The application of pseudotyping for transduction targeting (Croyle et al. 2004; 
Engelstadter et al. 2001; Miller et al. 1991) is limited by the range of available glycoproteins 
with useful infection tropisms. A more versatile strategy is the use of chimeric envelope 
proteins in which parts of the protein responsible for receptor binding are replaced with 
peptides (Gollan and Green 2002), ligands (Cosset et al. 1995; Kasahara et al. 1994) or single-
chain antibodies (Anliker et al. 2010; Somia et al. 1995) conferring binding to the desired 
receptors for viral entry. Additionally, adaptors, which are capable of associating with both 
the viral glycoprotein and the cellular receptor, can be used to mediate between virus and 
target cell (Boerger et al. 1999; Snitkovsky et al. 2001).  
Another concept is targeting by activation. Retroviral vectors displaying the amphotropic 
MLV Env containing the original receptor binding domain and elements coding for IL2 
(Maurice et al. 1999) or hepatocyte growth factor (HGF) (T. H. Nguyen et al. 1998) were 
generated. These vectors would allow binding of and entry to a broad range of cells. However, 
only upon cell activation due to binding of IL2 or HGF to their cognate receptor would lead to 
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significant transduction, as introducing proliferation enabled the progress of MLV provirus to 
the nucleus and subsequent integration and transgene expression (Maurice et al. 1999). 
Although lentiviral vector can infect non-dividing cells, blocks to transduction occur, for 
example in monocytes (Kootstra et al. 2000; Neil et al. 2001) and resting T cells (Dardalhon et 
al. 2001). Activation targeting can help to overcome such blocks. Problems encountered in such 
approaches include differentiation of stimulated cells or background infection in rapidly 
dividing cells (Verhoeyen and Cosset 2004). What these approaches have in common is that 
they often lead to significantly reduced infection rates (Galanis et al. 2001).  
Progress in transduction targeting has been made by separating binding and fusion properties 
(Lin et al. 2001; L. Yang et al. 2006b). This is possible as in several viral species, binding and 
fusion properties are independent features and fusion activity is triggered by different stimuli, 
i.e. low pH after endocytosis (L. Yang et al. 2006b). Most promising candidates for the use as 
heterologous fusogenic proteins in RV are genetically engineered variants of the Sindbis virus 
(SIN) glycoprotein (Morizono et al. 2005; L. Yang et al. 2006b; L. Yang et al. 2008b; H. Yang et 
al. 2008a; Ziegler et al. 2008), the influenza virus hemagglutinin (Lin et al. 2001; L. Yang et al. 
2006b) and measles virus surface glycoproteins (Anliker et al. 2010). In such a case, the use of 
adaptor systems may help to construct flexible targeting systems, as well as deposition of 
specific binding factors by using GPI-anchored proteins, especially in cases where binding and 
entry of viral particles are mediated by independent proteins, i.e. in trans (Lin et al. 2001; L. 
Yang et al. 2006b). The same basic viral particle can be modified with a range of binding 
properties to suit the specific needs of the applications. Antibody molecules, for example, in 
the form of single-chain antibody molecules, engineered to contain a GPI anchor, can provide 
a vast range of binding specificities. Summing up, the use of non RV/LV viral surface 
glycoproteins capable of inducing virus/cell fusion independent of specific binding taken 
together with a flexible such as an adaptor system or viral painting seems currently the most 
promising candidates for targeting applications. 
4. Outlook and discussion 
Due to their average size of 100 nm, RV and LV particles can be considered as 
bionanotechnological devices. Modification thus becomes the – in the field of nanotechnology 
– more commonly used term “functionalisation”. Multiple modifications could lead to using 
viral vectors as multifunctional platforms for biomedicine combined with other 
nanotechnological elements. For example, magnetic micro- and nanoparticles are already 
commercially available to allow the purification of proteins containing tags such as the 
histidine tag or Flag tag. GPI-anchored proteins used for painting of enveloped viral vectors 
have also been engineered to contain histidine tags, allowing the particles to be coated with 
GPI-anchored protein and attached to the viral vectors by means of the GPI-anchor. Or, 
alternatively, biolinker proteins such as streptavidin can potentially be modified at the 
genetic level to contain a GPI signal sequences, and as such, after production in a suitable 
expression system, can be purified as reactive reagents to link up with biotinylated 
nanoparticles. In both cases the recombinant GPI-anchored protein acts as a linker or 
interface between the organic viral particles and inorganic nanomaterials, either magnetic or 
fluorescent capabilities (or both). With such a system in place to functionalise the surface of 
viral vectors without affecting the viral infectivity pathway, one can imagine many 
biomedical applications such as targeting of gene therapy vectors in vivo to tumours using 
magnetic force and tracking via bioimaging techniques based on magnetic field, i.e. MRI or 
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high-sensitivity camera in vivo fluorescence imaging. However, with all of this in mind one 
must not forget the safety issues as the effects of such materials cannot always be predicted 
in biological systems, an issue that has already emerged for carbon nanotubes which would 
not have been expected to be as toxic as has proven to be the case in many instances (Patlolla 
et al. 2010; van der Zande et al. 2011). Sometimes the speed of development can lead to 
rashness when translating into the clinic, a fate that already befell gene therapy in some 
regards (Sheridan 2011), so the same mistakes should be avoided when mixing together 
such new technologies with clinically used viral vectors (Subbiah et al. 2010).  
5. Conclusions / summary 
RV/LV vectors are already proving to be useful delivery vehicles for gene therapy 
applications but in order to establish more efficient vectors for in vivo delivery, the viral surface 
can potentially be modified to provide better means of preparation, purification, 
concentration, detection, tracking, imaging, and targeting in order to not only successfully 
manufacture the product but also to navigate interactions within the patient and  infect pre-
defined target cells selectively. To achieve this aim several techniques may be employed for 
surface engineering or RV/LV vectors. Table 3 provides a concise overview of these 
techniques and the applications for which they have been used and may conceivably be used 
in the future. Pseudotyping has been used for targeting applications, however, can only make 
use of a limited amount of targeting options. Chimeric proteins have been used for labeling 
and targeting applications, and can be useful for immunomodulation approaches. Enrichment 
may be achieved as a secondary objective. Modifications employing GPI-anchored proteins 
may prove to be versatile and efficient; however, further research will be necessary. A similar 
assessment can be made for the use of membrane-bound adaptor systems and direct chemical 
modifications. Finally, combining different strategies will allow broadening possibilities for 
the surface modification of viral vectors considerably. 
 
Modification Comment Labelling Enrichment Modulation Targeting 
Pseudotyping 
 
limited 
possibilities    
X 
Chimeric 
Protein  
versatile, 
decreased 
infectivity 
X (x) (x) X 
GPI 
Modifications 
via budding 
versatile, time-
consuming  
(x) X (x) 
via painting 
flexible, quick, 
post-exit 
(x) (x) (x) (x) 
Adaptors 
soluble 
additional 
component, 
post-exit 
(x) (x) 
 
X 
membraneous flexible, versatile X X (x) X 
Chemical 
Modification  
flexible, quick, 
maybe post-exit 
X X X X 
Table 3. Methods for engineering RV/LV vector surfaces and potential applications.  
X applications mentioned in the text; (x) potential for future applications. 
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